Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive December 1, 2006 Joanna Breitstein	Confessions of a Serial Whistleblower Interview with Peter Rost, author of Whistleblower: Confessions from a Healthcare Hitman, about what it was like after her blew the whistle on Pfizer and Wyeth.
BusinessWeek March 20, 2006 Arlene Weintraub	Selling The Promise Of Youth The anti-aging industry is offering a dizzying array of hormones and supplements. Business is booming. But some remedies are risky, and the benefits are unproven.
Pharmaceutical Executive May 1, 2006 Ron Feemster	Teamsters v. Pfizer A New Jersey Teamsters local says Pfizer tricked them into paying for off-label Lipitor prescriptions. Do you have any questions about that? We do.
The Motley Fool December 24, 2009 Brian Orelli	Another Reason to Worry About Pfizer The FDA fails to approve Lyrica for treating anxiety.
BusinessWeek November 28, 2005 Arlene Weintraub	Human Growth Hormone: Unproven and Unsafe HGH is often hyped as a cure for aging. But as so with most fountains of youth, there's no proof that it works. And it can be harmful. But for now, off-label use of human growth hormone appears to be a growth industry.
The Motley Fool November 25, 2009 Brian Orelli	Still Enjoying Those Acquisitions, Pfizer? The drug company has inherited a lot in its acquisitions of Warner-Lambert, Pharmacia, and Wyeth. And of course, those 10,000 lawsuits.
BusinessWeek February 28, 2005 Amy Barrett	Pfizer's Funk Pfizer CEO Hank McKinnell helped pioneer the age of blockbuster drugs. The company now spends twice as much on sales and administrative expenses as it does on R&D. But a dearth of new products and fears over drug safety are hurting the entire industry. Is there a fix?
BusinessWeek December 18, 2006 Arlene Weintraub	Pfizer vs. the Counterfeiters Its suit against an Indian man alleging that he sold fake Viagra shows how hard it is to shut down online drug marketers.
BusinessWeek May 14, 2007 Arlene Weintraub	Schering-Plough Climbs Out Of Its Sickbed Fred Hassan said getting drugmaker Schering-Plough on its feet might take years. Investors are beginning to see the virtues of patience
BusinessWeek June 28, 2004 Amy Barrett	When Medicine And Money Don't Mix Do drugmakers have too much control over lab data?
BusinessWeek March 20, 2006	The Guru of Anti-Aging There's plenty doctors can do to control the effects of old age, says a leading light in the anti-aging medical movement.
BusinessWeek August 14, 2006 Arlene Weintraub	The Lawyer Is In At Pfizer Jeffrey Kindler's ascent reflects the new challenges drugmakers face.
The Motley Fool January 28, 2010 Brian Orelli	Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds.
BusinessWeek May 20, 2009 Maria Bartiromo	Pfizer's Kindler on Health-Care Reform and the Wyeth Deal Pfizer's CEO discusses its acquisition of Wyeth and its plan to provide some drugs for free to those without jobs and insurance.
The Motley Fool September 2, 2009 Brian Orelli	Pfizer's Paying $2.3 Billion Again? Oh, Wait, Never Mind. There are 17 articles on the Yahoo! Finance ticker feed announcing or discussing the $2.3 billion settlement Pfizer made with the Department of Justice.
The Motley Fool January 26, 2004 Rex Moore	Schering: Worst Still to Come The flailing pharma sees a sorry 2004.
BusinessWeek February 5, 2007	The Doctor Won't See You Now A host of forces is now converging to clamp down on hard-driving, gift-toting pharmaceutical pitchmasters who have been ambushing physicians for the last decade.
The Motley Fool October 9, 2008 Brian Orelli	When Science, Marketing, and Investing Collide How a pharmaceutical tries to sell more drugs can provide clues about its management.
InternetNews February 10, 2005 Tim Gray	Microsoft and Pfizer After Viagra Spammers Redmond and the pharmaceutical giant team up to file lawsuits to fight selling and advertising of knock-off drugs.
The Motley Fool December 29, 2009 Brian Orelli	Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others.
The Motley Fool January 8, 2010 Brian Orelli	Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands.
The Motley Fool February 2, 2005 Brian Gorman	Pfizer's Troubling Trust Issue The company is in danger of losing the public's confidence.
BusinessWeek July 8, 2010 Simeon Bennett	Pfizer: Civil Suits for Drug Counterfeiters Pfizer's new tactics against fake drug peddlers have allowed it to recoup more than $5 million. That's still a fraction of its lost sales.
The Motley Fool March 30, 2011 Brian Orelli	How to Play the Pfizer Breakup (If It Happens) The sum of the parts could be worth more than the whole.
The Motley Fool February 2, 2010 Brian Orelli	Foolish Forecast: First Look at Pfizer Plus With the addition of Wyeth last quarter, there's no doubt Pfizer is larger, but whether that bigger size translates into savings that boosts profits remains to be seen.
The Motley Fool December 6, 2011 Brian Orelli	Pfizer Faces Firing Line A panel of outside experts will help decide Inlyta's fate.
The Motley Fool September 2, 2010 Brian Orelli	Pfizer Takes an Orphan Into the Fold Pfizer is likely pursuing FoldRx's pipeline and expertise in rare diseases.
The Motley Fool March 26, 2009 Brian Orelli	Big Pharma's R&D Model Is Broken Bigger isn't always better.
The Motley Fool May 18, 2009 Brian Orelli	Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship.
Managed Care October 2001 Bob Carlson	Trying To Get Control of Drug Costs, Florida Earns Kudos -- and a Lawsuit Pharmaceutical Research and Manufacturers of America (PhRMA) filed suit against Florida's Agency for Health Care Administration, challenging a new Medicaid formulary that requires manufacturers to pay supplemental rebates to have their drugs included...
Managed Care December 2004 John Carroll	Pfizer Touts Medicaid Data In Arguing That DM Works The pharmaceutical giant Pfizer says that its disease management program saved Florida $42 million, but a state watchdog group remains unconvinced.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today.
The Motley Fool April 7, 2009 Brian Orelli	Pfizer's Mind Meld Pfizer has a plan now for its structure after its acquisition of Wyeth -- including keeping eight senior executives from its new purchase.
The Motley Fool November 13, 2009 Brian Orelli	Questioning Pfizer's Integrity Pfizer's epilepsy drug Neurontin has had generic competition for a few years, but it's still plaguing the pharmaceutical giant.
The Motley Fool September 16, 2008 Brian Lawler	Pfizer Puts Safety First Increased FDA scrutiny may motivate the pharmaceutical's new drug-safety site.
The Motley Fool October 19, 2009 Brian Orelli	Foolish Forecast: A Last Look at "Mini" Pfizer In advance of Pfizer's last earnings report before their acquisition of Wyeth, analysts expect a drop in sales and a bigger bottom line decrease.
The Motley Fool June 24, 2011 Brian Orelli	Come on, Pfizer, Not Even a Little Hint? Remoxy is rejected, but why?
The Motley Fool May 4, 2010 Brian Orelli	Earnings Growth Trumps Revenue Growth, Except Here A solid quarter for Pfizer, but is there more in the tank?
BusinessWeek August 26, 2010 Bess Levin	The Old and the Beautiful How the boomers' fear of mortality became an $88 billion annual industry is described in Arlene Weintraub's book, Selling the Fountain of Youth: How the Anti-Aging Industry Made a Disease Out of Getting Old -- And Made Billions
The Motley Fool January 26, 2009 Brian Orelli	Deja Vu All Over Again There's hardly anything to like about Pfizer's deal to buy Wyeth. This is what got Pfizer into its problem in the first place.
Pharmaceutical Executive March 1, 2009 Walter Armstrong	Attack of the Monster Merger Just when you thought it was safe to go back into M&A, the mega merger returns. What's right about Pfizer-Wyeth, and what's scary.
The Motley Fool September 30, 2010 Brian Orelli	Chief Justice Roberts Sold Pfizer. Should You? Maybe, but not for the same reason.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool June 15, 2010 Brian Orelli	Pfizer Focuses, Investors Should Cheer The culling of the pipeline continues at Pfizer. While that's bad news for partners that signed on with the company or with Wyeth before the merger it's a good move for Pfizer.
The Motley Fool October 7, 2004 Brian Gorman	Pfizer Will Weather the Storm The company will likely come out on top regardless of the outcome of the latest controversies. Pfizer remains a quality choice for long-term investors.
The Motley Fool September 30, 2009 Brian Orelli	Bigger Size, Lower Returns History is not on Merck and Schering's side.
The Motley Fool May 17, 2004 Roger Nusbaum	Diagnosing Pfizer Can Pfizer, the pharmaceutical company, outperform the market?
The Motley Fool February 25, 2010 Brian Orelli	13 Is Pfizer's Lucky Number Inherited from Wyeth, Prevnar 13 could be a goldmine for Pfizer.
The Motley Fool April 4, 2011 Brian Orelli	Pfizer Tests the Breakup Waters The company announced today that it found a buyer for its Capsugel unit, which will bring in a cool $2.4 billion.
Chemistry World February 2, 2011 Andy Extance	Pfizer to close historic UK site Most of the 2400 people employed at the Pfizer site in Sandwich, UK, will be made redundant over the next 18-24 months as the US pharma giant restructures its research operations.